Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue

Carcinogenesis

Volumn 32, Issue 6, 2011, Pages 913-920

  Jahns, F ^a,b   Wilhelm, A ^a,b   Jablonowski, N ^a   Mothes, H ^a   Radeva, Mariya ^b   Wolfert A ^a   Greulich, K O ^b   Glei, M ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLOOXYGENASE 2; MESSENGER RNA; OSTEOPONTIN; PROSTAGLANDIN E2;

ARTICLE; COLON ADENOMA; COLON CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79958205596     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr061     Document Type: Article

References (62)

1. Ferlay,J. et al. (2010) Globocan 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr. (08 February 2011, date last accessed).
2. Bingham,S.A. et al. (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition EPIC): an observational study. Lancet, 361, 1496-1501.
3. World Cancer Research Fund and American Institute for Cancer Research. (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. American Institute for Cancer Research, Washington, DC.
4. Beyer-Sehlmeyer,G. et al. (2003) Butyrate is only one of several growth inhibitors produced during gut flora-mediated fermentation of dietary fibre sources. r. J. Nutr., 90, 1057-1070.
5. Pool-Zobel,B.L. et al. (2005) Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics. Carcinogenesis, 26, 1064-1076.
6. Scharlau,D. et al. (2009) Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary ibre. Mutat. Res. 682, 39-53.
7. Gibson,P.R. et al. (1999) Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis, 20, 539-544.
8. Oshima,M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
9. Wai,P.Y. et al. (2005) Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. arcinogenesis, 26, 741-751.
10. Mazzali,M. et al. (2002) Osteopontin-a molecule for all seasons. QJM, 95, 3-13.
11. Fedarko,N.S. et al. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 7, 4060-4066.
12. Rohde,F. et al. (2007) Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int. J. Cancer, 121, 1717-723.
13. McAllister,S.S. et al. (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 133, 994-1005.
14. Wai,P.Y. et al. (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev., 27, 103-118.
15. Funk,C.D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 294, 1871-1875.
16. McLean,M.H. et al. (2008) COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology, 52, 806-15.
17. Soumaoro,L.T. et al. (2004) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res., 10, 8465-471.
18. Greenhough,A. et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30, 377-386.
19. Lev-Ari,S. et al. (2005) Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res., 11, 6738-6744.
20. Zhao,J. et al. (2008) Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology, 135, 956-968.
21. Schaeferhenrich,A. et al. (2003) Putative colon cancer risk factors damage global DNA and TP53 in primary human colon cells isolated from surgical samples. ood Chem. Toxicol., 41, 655-664.
22. Rogler,G. et al. (1998) Establishment of long-term primary cultures of human small and large intestinal epithelial cells. Lab. Invest., 78, 889-890.
23. Pfaffl,M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res., 29, e45.
24. Bradford,M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. iochem., 72, 248-254.
25. Kargman,S.L. et al. (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556-2559.
26. Agrawal,D. et al. (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst., 94, 13-521.
27. Papafili,A. et al. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. rterioscler. Thromb. Vasc. Biol., 22, 1631-1636.
28. Zhang,Z.H. et al. (2004) Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells. World J. Gastroenterol., 10, 954-2957.
29. Pajari,A.M. et al. (1998) Role of red meat and arachidonic acid in protein kinase C activation in rat colonic mucosa. Nutr. Cancer, 32, 86-94.
30. Schultz,J. et al. (2009) The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-yb transcription factor. Mol. Carcinog., 48, 14-23.
31. Chambers,A.F. et al. (1992) Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. nticancer Res., 12, 43-47.
32. Morimoto,I. et al. (2002) Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer, 33, 270-278.
33. Wang,K.X. et al. (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev., 19, 333-345.
34. Courter,D. et al. (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One, e9633.
35. Lee,S.H. et al. (1992) Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem., 267, 5934-25938.
36. Nagasaki,T. et al. (1997) Osteopontin gene expression and protein synthesis in cultured rat mesangial cells. Biochem. Biophys. Res. Commun., 233, 81-85.
37. Mann,J.R. et al. (2006) Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer rogression. Cancer Res., 66, 6649-6656.
38. Ozaki,N. et al. (2010) Identification of genes involved in gentamicininduced nephrotoxicity in rats-a toxicogenomic investigation. Exp. Toxicol. Pathol., 62, 55-566.
39. Takemoto,M. et al. (1999) Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun., 58, 722-726.
40. Hamer,H.M. et al. (2008) Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther., 27, 104-119.
41. Tabuchi,Y. et al. (2002) Identification of genes responsive to sodium butyrate in colonic epithelial cells. Biochem. Biophys. Res. Commun., 293, 1287-1294.
42. Christensen,B. et al. (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem. J., 390, 285-292.
43. Christensen,B. et al. (2007) Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J. Biol. hem., 282, 19463-19472.
44. Crawford,H.C. et al. (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. ancer Res., 58, 5206-5215.
45. Anborgh,P.H. et al. (2009) New dualmonoclonal ELISA formeasuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin. Chem., 55, 895-903.
46. Senger,D.R. et al. (1994) Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-inding domain. Mol. Biol. Cell, 5, 565-574.
47. Sharma,P. et al. (2010) Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol. ancer, 9, 178.
48. Tong,X. et al. (2004) Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem. Biophys. Res. Commun., 317, 463-471.
49. Chen,L.C. et al. (2004) Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res., 64, 694-3700.
50. DeWitt,D.L. et al. (1993) Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch. Biochem. Biophys., 306, 94-102.
51. Tong,X. et al. (2005) Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J. iol. Chem., 280, 15503-15509.
52. Dixon,D.A. (2003) Regulation of COX-2 expression in human cancers. Prog. Exp. Tumor Res., 37, 52-71.
53. Usami,M. et al. (2008) Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res., 28, 321-328.
54. Jung,J.W. et al. (2005) Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer Lett., 225, 199-206.
55. Backlund,M.G. et al. (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem., 280, 3217-3223.
56. Panel,V. et al. (2006) Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett., 243, 255-263.
57. Seo,T. et al. (2009) Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch., 454, 667-676.
58. Murakami,M. et al. (1999) Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic athways. J. Biol. Chem., 274, 3103-3115.
59. Murakami,M. et al. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with yclooxygenase-2. J. Biol. Chem., 275, 32783-32792.
60. Pugh,S. et al. (1994) Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut, 35, 675-678.
61. Sherratt,P.J. et al. (2003) Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive gents. Biochem. Pharmacol., 66, 51-61.
62. Hughes-Fulford,M. et al. (2005) Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis, 6, 1520-1526.